Predictive Oncology Inc

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Predictive Oncology Inc advances in cancer research and cost optimization

POAI's Q2 2024 performance reflects progress in research, technology, and cost optimization strategies.
While facing challenges in financial metrics, the company's focus on innovation and shareholder value creation positions it for long-term success.
Opportunities lie in leveraging AI capabilities, strategic partnerships, and revenue growth initiatives to drive future growth and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Predictive Oncology Inc. (NASDAQ:POAI) said it has appointed healthcare commercial and business development veteran Dr Veena Rao to its board of directors. Dr Rao will replace David Smith, who is stepping down but will remain an advisor to the board and assume duties as legal counsel to the company.

Predictive Oncology appoints healthcare commercial and business development veteran to its board

Rekor Systems Inc

SoundHound AI Inc

Artificial intelligence is one of the hottest stories of the year. Investors who believe in the technology, or who are simply looking to find growth wherever they can, are flocking into AI stocks.

3 Undiscovered AI Stocks Set to Dominate the Market

Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares.

Predictive Oncology Announces Reverse Stock Split

Bright Minds Biosciences

Genprex

Heliogen

Inovio Pharmaceuticals

mCloud Technologies Corp

National CineMedia

NeuroBo Pharmaceuticals Inc

Oncternal Therapeutics Inc

Vascular Biogenics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 10 Under $1 To Watch This Week

MINNEAPOLIS, April 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, announced today that the Company's Special Meeting of Stockholders was convened at 3:00 p.m. Central Time on April 17, 2023 and adjourned without any business being conducted, due to lack of the required quorum. Due to the lack of quorum, the Special Meeting was adjourned to allow additional time for the Company's stockholders to vote on the proposal to approve an amendment to the Company's certificate of incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of not less than one-for-two (1:2) and not more than one-for-twenty-five (1:25), with the exact ratio to be set at a whole number within this range as determined by our Board of Directors. At the Special Meeting, the stockholders are also being asked to approve a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies for approval of the reverse split proposal, in the event that there are not sufficient votes at the time of the Special Meeting to approve such proposal.

Predictive Oncology Adjourns Special Meeting of Stockholders

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 Under $1 To Watch This Week

Penny stocks under $1 to watch before next week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 4 Under $1 To Watch Before Next Week

Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key thought leaders in their fields to guide the company's scientific initiatives and growth strategy.

Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board

EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, is pleased to announce the appointment of Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board. In this role, Dr. Reinhard will serve alongside other key thought leaders in their respective fields to guide the Company's scientific initiatives and growth strategy.

Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board

Predictive Oncology Inc. (NASDAQ:POAI) said it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases, to pursue a novel method to enhance Integra's ability to use gene editing for future cancer therapies. “Our novel formulation technology and protein expression experience positions Predictive Oncology to help advance Integra's goals,” said Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology.

Predictive Oncology partners with Integra Therapeutics to advance gene therapy

EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases.

Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy

Predictive Oncology, Inc. (NASDAQ:POAI ) Q4 2022 Earnings Conference Call March 22, 2023 12:00 PM ET Company Participants Theresa Ferguson - Senior Director of Marketing Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Conference Call Participants Michael Broadbent - Bedrock Group, Inc. Danny Garcia - KSU Brenda Thompson - IBM Operator Good day and thank you for standing by. Welcome to the Predictive Oncology, Inc. Q4 2022 Earnings Conference Call.

Predictive Oncology, Inc. (POAI) Q4 2022 Earnings Conference Call Transcript

Predictive Oncology Inc. (NASDAQ:POAI) has highlighted the “untapped” potential of its PEDAL drug discovery platform alongside its results for the year ended December 31, 2022.  “I assumed the role of chief executive officer of Predictive Oncology because, as a board member, I was able to see first-hand the untapped potential of the company's assets, notably its proprietary PEDAL drug discovery engine, which leverages our proprietary artificial intelligence and machine learning capabilities to facilitate more efficient oncologic drug discovery and enable drug development,” said Raymond F Vennare, chief executive officer and chairman of Predictive Oncology in the results statement.

Predictive Oncology hails potential of PEDAL drug discovery platform as it reports 2022 results

EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update. The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year.

Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update

Predictive Oncology Inc. (NASDAQ:POAI) and Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK (CRUK), have announced a partnership to drive the development of oncology drugs utilizing Predictive Oncology's PEDAL platform. Minneapolis, Minnesota-based Predictive Oncology said the collaboration will utilize its PEDAL technology to evaluate Cancer Research Horizons' pre-clinical drug inhibitors of Glutaminase to determine which cancer types and patient populations are most likely to respond to treatment with these compounds.

Predictive Oncology and Cancer Research Horizons partner up to pursue development of cancer drugs

EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology's PEDAL™ platform.

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs

EAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on March 27, 2023. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on March 27, 2023. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series F Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series F Preferred Stock).

Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development

Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner

Predictive Oncology Inc. (NASDAQ:POAI) CEO Raymond F Vennare told investors that the company is focusing on conducting transactions with biopharmaceutical partners and driving the adoption of its proprietary PEDAL drug discovery platform.   “We have consolidated infrastructure, merged assets, reassigned personnel and gained domain expertise, thereby creating operational efficiencies and lowering overhead,” Vennare said in a letter to shareholders, “In the process of this consolidation and reassessment of all company assets and core competencies, we have identified currently existing opportunities which we believe will significantly broaden our intellectual property portfolio.

Predictive Oncology highlights successful restructuring and strategic partnerships in letter to shareholders

EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncologic drug discovery and enable drug development, today issued the following letter to shareholders:

Predictive Oncology Issues Letter to Shareholders

Predictive Oncology Inc. (NASDAQ:POAI) and Cvergenx Inc forged an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence (AI) approach to personalized radiotherapy and drug discovery. Minneapolis, Minnesota-based Predictive Oncology, which has a unique approach to leveraging AI in oncology drug discovery, said the collaboration will leverage the combined power of both the firm's proprietary technologies and domain expertise for a common purpose.

Predictive Oncology and Cvergenx partner up to develop first-ever genomics-based AI approach to personalized radiation therapy and drug discovery

EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery.

Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence

Amesite Operating

Inuvo

Lantern Pharma

Remark Hlds

Oblong

Powerbridge Technologies Co Ltd

AI penny stocks provide investors with higher-risk, higher-upside exposure to companies specializing in developing or utilizing artificial intelligence technology. Since these stocks trade at a relatively low price per share and may be relatively unproven, operating in niche areas of the market, there's more to be gained by a correct bet on these stocks.

7 AI Penny Stocks That Could Skyrocket in 2023

Predictive Oncology Inc. (NASDAQ:POAI) has announced the launch of ACE (Accelerating Compound Exploration), a program to advance oncology drug development initiatives with academic and research institutions. The Eagan, Minnesota-based company said it created ACE to grant early-stage academic drug development groups and technology transfer offices access to its PEDAL platform.

Predictive Oncology launches ACE program to partner with academic and research institutions to advance drug discovery initiatives

Guardforce AI Co Ltd

Aurora Mobile Ltd - ADR

WeTrade Group Inc

ChatGPT AI Penny Stocks To Watch As Machine Learning Tech Heats Up The post 4 ChatGPT Stocks To Watch In February Trading For Pennies appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Predictive Oncology Inc Stock (POAI)